Form 4: Fate Therapeutics Director Timothy Coughlin Granted Stock Options

Director Timothy Coughlin received a grant of stock options from Fate Therapeutics on June 7, 2024, according to a Form 4 filing.

Summary

• On June 7, 2024, Timothy Coughlin, a director of Fate Therapeutics, was granted stock options to purchase 40,000 shares of common stock.
• The exercise price of these options is $3.68 per share.
• The options vest on the earlier of June 7, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on June 7, 2034.
• This grant was made under the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders. The sentiment is moderately positive due to the incentive structure.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the Board of Directors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) previously used similar equity-based compensation to attract and retain board members.
• The size and vesting schedule of the options are generally in line with industry practices for companies of Fate Therapeutics' size and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• The director benefits from the potential future value of the stock options.

Key Dates